Stories

What Makes a Peptide CDMO Commercially Ready?

Learn More

How to Reduce Small Molecule API Manufacturing Delays in 2027

Learn More

Continuous Flow Manufacturing for APIs: Benefits, Challenges, and the New Regulatory Landscape

Learn More

Advantages of a Pure-Play API CDMO for Biotech and Pharma Companies

Learn More

6 Properties of API Synthesis That Affect Yield, Purity, and Delivery Timelines

Learn More

What to Expect from Neuland Labs at CPHI Milan 2026

CPHI Milan 2026 is the Milan edition of CPHI, the pharmaceutical industry's largest ingredient and manufacturing trade show. It runs from 6 to 8 October 2026 at Fiera Milano in Milan, Italy. For API development, it matters because it puts sourcing decisions in front of the people who make them.

Learn More

Which Small Molecule API Partner Is Right for Clinical Trials?

Learn More

GLP-1 Peptide Manufacturing: A CDMO Buyer's Guide

GLP-1 peptides require production volumes far beyond typical peptide drugs, often reaching multi-ton annual output.

Learn More

Pharmaceutical API Stability: Protecting API Quality from Development to Commercial Supply

API stability requires continuous monitoring and phase-appropriate testing throughout a molecule's development lifecycle to ensure quality, shelf life, and regulatory compliance from early development through commercial supply.

Learn More